IO-108,pembrolizumab,cemiplimab 
Immune-Onc Therapeutics,Merck,Regeneron
['pembro', 'io-108']
we have great news to share at #aacr23! data from our ph 1 study show encouraging clinical benefit for io-108 as a monotherapy &amp; when combined with pembrolizumab. don't miss the oral presentation on tue., apr. 18 at 4:05-4:15 pm (ct040). read more at: 
Science at Our Core. Patients in Our Hearts.